August 13, 2021

We hope this correspondence finds you well and enjoying the final weeks of summer. As a result of a recent Department of Health recommendation, The Learning Lamp and Ignite Education Solutions has updated portions of the COVID-19 Handbook:

- **Child Care Center Positive COVID-19 Test Procedure (page 4):**
  - The infected location will be required to wear masks in the center for 14 days following the positive test, regardless of vaccination status.

- **Quarantine for Vaccinated Individuals (page 6):**
  - On July 30, 2021, the Pennsylvania Department of Health recommended that Vaccinated Individuals who have had a known exposure to someone with suspected or confirmed COVID-19 to be tested 2-5 days after exposure, and should wear a mask in public indoor settings for 14 days or until they receive a negative test. The Learning Lamp highly recommends following this guidance from the DOH.

The most up-to-date COVID-19 Handbook can always be accessed by clicking here. The updates above are highlighted throughout the handbook.

In addition, a recent article from CNBC poses some key points on a booster shot to the Johnson and Johnson vaccination:

- A new study from a lab at NYU raises serious questions about the effectiveness of J&J’s single-dose vaccine against the highly contagious delta variant.
- CNBC’s Meg Tirrell spoke to the lead author of the study who told her that the study suggests, “one should at least consider a second vaccination, a second shot” with the J&J vaccine, either of the same vaccine, or one from Pfizer or Moderna.
- “I do think that those one-shot J&J’s should be given the opportunity, while we complete our clinical trial… I’m already telling my patients to do it, if they can get access to it,” said an intensive-care unit and lung doctor Dr. Vin Gupta.

The article, titled “Dr. Vin Gupta encourages J&J vaccine recipients to get a Pfizer or Moderna booster,” can be accessed by clicking here.

Finally, yesterday, the FDA amended the emergency use authorizations for both Pfizer and Moderna to allow for the use of an additional dose in certain immunocompromised individuals, specifically solid organ transplant recipients or those who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. More information can be accessed by clicking here.

If you have any questions on the above policy changes, please reach out to anyone in the HR Department.

Previous communication documents can be accessed by clicking here.